Abstract Multiple system atrophy (MSA) is a fatal, rapidly progressive atypical parkinsonism that responds poorly to Parkinson’s disease (PD) medications, and diagnostic precision remains a critical unmet need. Earlier, accurate diagnosis would give patients realistic prognostic expectations and enable timely clinical-trial enrollment. We sought plasma biomarkers discriminating MSA from PD.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ming-Che
Contact Ming-Che, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack